Description

Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial[1][2].—Neuroscience-Neuromodulation–C55H96N14O13—Brain Res. 2023 Oct 5:1821:148619.|Oral Dis. 2023 Oct 9.|Research Square Print. 2022 Aug.-[1]Boengler K, et al. Connexin 43 impacts on mitochondrial potassium uptake. Front Pharmacol. 2013 Jun 6;4:73.|[2]Wang N, et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2013 Jan;108(1):309.–1507930-57-5–1161.44—-NCCCC[C@H](N)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@H](C(O)=O)CCCCN)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O–Cardiovascular Disease–10 mM in DMSO–Gap Junction Protein—-Cytoskeleton–Peptides